Identification of FDA-Approved Drugs and Bioactives that Protect Hair Cells in the Zebrafish (Danio rerio) Lateral Line and Mouse (Mus musculus) Utricle
- First Online:
- Cite this article as:
- Ou, H.C., Cunningham, L.L., Francis, S.P. et al. JARO (2009) 10: 191. doi:10.1007/s10162-009-0158-y
The hair cells of the larval zebrafish lateral line provide a useful preparation in which to study hair cell death and to screen for genes and small molecules that modulate hair cell toxicity. We recently reported preliminary results from screening a small-molecule library for compounds that inhibit aminoglycoside-induced hair cell death. To potentially reduce the time required for development of drugs and drug combinations that can be clinically useful, we screened a library of 1,040 FDA-approved drugs and bioactive compounds (NINDS Custom Collection II). Seven compounds that protect against neomycin-induced hair cell death were identified. Four of the seven drugs inhibited aminoglycoside uptake, based on Texas-Red-conjugated gentamicin uptake. The activities of two of the remaining three drugs were evaluated using an in vitro adult mouse utricle preparation. One drug, 9-amino-1,2,3,4-tetrahydroacridine (tacrine) demonstrated conserved protective effects in the mouse utricle. These results demonstrate that the zebrafish lateral line can be used to screen successfully for drugs within a library of FDA-approved drugs and bioactives that inhibit hair cell death in the mammalian inner ear and identify tacrine as a promising protective drug for future studies.
KeywordsFDA libraryzebrafishhair cellprotectionototoxicityaminoglycoside
Prevention of hair cell death is an important target for the prevention of hearing loss. Aminoglycoside ototoxicity due to hair cell death is clinically important and useful for studying hair cell loss (Forge and Li 2000; Forge and Schacht 2000; Schacht 1998). Many agents have been investigated as protective agents against aminoglycoside ototoxicity, but only a few, such as D-methionine and aspirin (Campbell et al. 2007; Sha et al. 2006) have reached the point of clinical trials, with mixed results (Rizzi and Hirose 2007). Since clinical trials are costly, time-intensive, and highly regulated, it is helpful to focus efforts on protective drugs that have certain beneficial characteristics and thus have a relatively high probability of reaching clinical trials.
Previous studies have demonstrated the utility of the zebrafish for studying aminoglycoside and cisplatin-induced hair cell death (Harris et al. 2003; Ou et al. 2007; Ton and Parng 2005; Williams and Holder 2000) as well as screening for protective (Owens et al. 2008) and ototoxic drugs (Chiu et al. 2008). This report describes the use of a library composed of FDA-approved drugs and bioactive compounds (NINDS Custom Collection II) to screen for candidate protective drugs. While this library has been used previously in other systems for the identification of promising compounds with neuroprotective capacity (Wang et al. 2005; Rothstein et al. 2005), this is the first reported use of this library to screen for drugs that protect against hair cell loss. This library has several advantages. The process of taking a new drug from preclinical validation to FDA approval is known to be long, arduous, and expensive. If an effective drug can be found among drugs that have been used in humans for other conditions, it may be possible to shorten this process considerably and reduce costs. In addition, a great deal of background information, including drug targets, is available for commercially approved drugs.
For drugs that protect against aminoglycoside-induced hair cell death to be candidates for clinical trials, we propose that a number of characteristics are desirable. (1) Drugs must be safe for administration in humans, preferably systemically rather than requiring local application, and with an acceptable toxicity profile; (2) they must cross the blood–brain barrier; (3) they must protect over a wide range of aminoglycoside doses; (4) they must not inhibit aminoglycoside uptake (i.e. inhibition of downstream cell death pathways); (5) they must not affect the bactericidal capacity of aminoglycosides; and (6) they must offer protection of mammalian hair cells.
This report describes the results of the screen of the NINDS Custom Collection library as well as further evaluation of the candidate drugs in the lateral line and mouse utricle with regards to the “ideal” drug characteristics described previously. Through these evaluations, tacrine (5-amino-1,2,3,4-tetrahydroacridine) was identified as a particularly promising drug for further in vivo studies in mammals and potentially for clinical trials.
Materials and methods
All zebrafish procedures described have been approved by the University of Washington Animal Care and Use Committee. All mouse procedures described have been approved by the University of Washington Animal Care and Use Committee and the Medical University of South Carolina Animal Care and Use Committee.
Zebrafish (Danio rerio) embryos of the AB wild-type strain were produced by paired matings of adult fish maintained at 28.5°C in the University of Washington zebrafish facility (Westerfield 2000). Embryos were maintained at a density of 50 embryos per 100 mm2 petri dish in embryo media (1 mM MgSO4, 120 μM KH2PO4, 74 μM Na2HPO4, 1 mM CaCl2, 500 μM KCl, 15 μM NaCl, and 500 μM NaHCO3 in dH2O). At 4 days post-fertilization (dpf), larvae were fed live Paramecia.
Three- to six-week-old CBA/J male mice were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN, USA) and maintained in the University of Washington Animal Care Facility or the Medical University of South Carolina Animal Care Facility.
For quantification of hair cell loss, live 5 dpf zebrafish larvae were exposed to 3 μM fixable FM1-43FX (Invitrogen, Carlsbad, CA, USA; F-35355) for 30 s followed by three rinses in embryo medium. After euthanasia and fixation in 4% paraformaldehyde overnight 4°C, labeled fish were then mounted in Fluoromount-G (SouthernBiotech, Birmingham, AL, USA; 0100-01) for fluorescence microscopy (Fig. 1C, D).
The NINDS Custom Collection II (Microsource, Gaylordsville, CT, USA) library consists of 1,040 drugs and bioactive compounds, divided into 13 plates of 80 drugs each. All drugs are dissolved in DMSO at 10 mM concentration and are unlabeled. We note that not all drugs in this library are FDA-approved, but all have known biological activity. In addition to the US FDA-approved compounds, many are approved for clinical use in other countries but have not received FDA approval.
Five days post-fertilization zebrafish larvae were first labeled with YO-PRO1 as described above. One fish in 150 μL of embryo medium was transferred into each well of a 96-well optical base plate (Nunc, Rochester, NY, USA) with 12 columns numbered 1 to 12, and eight rows labeled A to H. A multichannel pipettor was used to transfer 1.5 μL of each drug into each well in columns 2 through 11 for a 1:100 dilution and a final concentration of 100 μM with 1% DMSO. After pretreatment with the library drug for 1 h, 1.8 μL of neomycin (Sigma, St. Louis, MO, USA) was added to each well for a final concentration of 200 μM neomycin. Previous studies from our group have shown that this exposure condition leads to almost complete loss of hair cells in every neuromast (Harris et al. 2003; Murakami et al. 2003; Santos et al. 2006). After 1 h of neomycin exposure, the plate was placed directly on the automated stage of an inverted epifluorescent Zeiss Axiovert 200M microscope and hair cell survival was rapidly assessed. Hair cell protection was graded on a scale of 0 (no protection) to 4 (complete protection) as has been described previously (Chiu et al. 2008). Approximately five to seven neuromasts were examined per fish at ×20 to ×40 magnifications. Wells in the first column of the 96-well plate contained a negative control (pretreatment with 1% DMSO followed by 200 μM neomycin). Wells in the last column of the plate contained a positive control (pretreatment with 1% DMSO, no neomycin added). Screening of one 96-well plate typically required approximately 30 min, meaning that the last well examined had approximately 30 additional minutes of exposure to neomycin.
Dose–response functions were performed to determine the effective dose range for each protective compound and to determine the efficacy of an optimal dose of drug against a range of neomycin concentrations.
Five days post-fertilization zebrafish larvae in groups ranging from 10–15 fish were prelabeled with the fixable dye FM1-43FX. To test optimal concentrations of drug, larvae were treated for 1 h with the candidate drug at 0, 10, 50, 100, and 200 μM concentrations, followed by 200 μM neomycin for 1 h with the candidate drug still present. To test the efficacy against a range of neomycin, larvae were treated with the optimal concentration (greatest protection with least toxicity) of protective drug for 1 h followed by treatment with 0, 100, 200, and 400 μM neomycin for 1 h with the candidate drug still present. Fish were then euthanized and immediately fixed overnight at 4°C in 4% paraformaldehyde, rinsed in phosphate-buffered solution (PBS), and mounted in Fluoromount-G on 25 × 60 mm coverslips for imaging and counting. Hair cell counts were determined using fluorescence microscopy using a Zeiss Axioplan II microscope to count intact FM1-43FX labeled hair cells from the SO1, SO2, O1, and OC1 (Raible and Kruse 2000) neuromasts on one side of each fish. Typical hair cell counts for these four neuromasts are 8(±2), 12(±2), 10(±3), and 7(±3), respectively (Harris et al. 2003; Ou et al. 2007). Previous work has demonstrated that there is no significant differential sensitivity to aminoglycosides among neuromasts (Harris et al. 2003). Total hair cell counts were determined by adding the hair cell counts from the four neuromasts. Hair cell survival as a percentage of the control was calculated by dividing the total number of hair cells of each fish in the experimental group by the mean total number of hair cells in an undamaged control group (1% DMSO pretreatment, no neomycin). Up to 2% DMSO does not protect against neomycin-induced hair cell death in the zebrafish lateral line. In addition, 2% DMSO does not independently cause hair cell death (unpublished observations).
Twenty-four-hour survival counts
Five days post-fertilization zebrafish were prelabeled with FM1-43, pretreated with the candidate drug for 1 h, followed by 1 h of 200 μM neomycin with the candidate drug still present. Both drugs were then washed out and zebrafish were allowed to recover for 24 h. Zebrafish were then euthanized and fixed in 4% paraformaldehyde, mounted, and imaged. Hair cell survival in treated groups was compared to undamaged controls treated with only 1% DMSO for 1 h followed by 24 h of “recovery”, as well as damaged controls treated with 1% DMSO followed by 1 h of 200 μM neomycin and a 24-h recovery.
Five days post-fertilization zebrafish were prelabeled with FMI-43FX, pretreated with protective drug for 1 h then washed five times in embryo medium. Fish were then exposed to neomycin for 1 h and fixed and mounted. Hair cell survival in treated groups was compared to undamaged controls treated only with 1% DMSO, as well as damaged controls treated with 1% DMSO followed by an identical neomycin exposure.
After pretreatment with the candidate drug for 1 h, 5 dpf zebrafish were exposed to 200 μM Texas-Red conjugated gentamicin (TR-Gent; Steyger et al. 2003) while still in the presence of the candidate drug. Zebrafish were washed and then examined in vivo using fluorescence microscopy at 3 and 10 min after addition of the TR-Gent to assess uptake. Neuromasts were imaged with a Zeiss Axioplan II microscope using a Texas-Red filter set at ×40 magnification. These experiments were repeated in triplicate for each drug. Control neuromasts exposed to unconjugated Texas Red alone did not demonstrate any uptake.
Transduction channel integrity
After pretreatment with the candidate drug for 1 h, 5 dpf zebrafish were exposed to 4 μM FM1-43 for 45 s and washed in embryo medium. Neuromasts were then imaged in vivo using fluorescence microscopy at 3 min after addition of FM1-43 to assess uptake. Neuromasts were imaged using a FITC filter set at ×40 magnification. These experiments were repeated in triplicate for each drug. Only short duration FM1-43 exposures were tested because FM1-43 is known to be taken up by endocytotic pathways with longer exposures (Gale et al. 2001; Seiler and Nicolson 1999).
Mouse utricle experiments
Protective effects for cepharanthine and tacrine were examined in the mouse utricle. Mature mice (3 to 6 weeks of age) were sacrificed by overdose of nembutal. Utricles were then removed from the temporal bones using sterile technique and cultured in tissue culture plates (Cunningham et al. 2002) with a 2:1 mixture of basal medium Eagle and Earle’s balanced salt solution, with 5% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Utricles were cultured for 24 h with cepharanthine or tacrine at 0, 1, 10, 50, and 100 μM concentrations to determine if there was any hair cell toxicity. Once the highest nontoxic dose was determined, utricles were treated with 4 h of pretreatment with the candidate drug, followed by 24 h with 2 mM neomycin.
After treatment, otoconia were removed by a steady stream of phosphate-buffered solution. The utricles were then fixed overnight in 4% paraformaldehyde at 4°C. After rinsing in PBS, utricles were placed in blocking solution (2% bovine serum albumin, 0.4% normal goat serum, 0.4% normal horse serum, 0.4% Triton X-100 in PBS) for 3 h at room temperature. Utricles were then double labeled with a monoclonal antibody against calmodulin (1:200; Sigma, St. Louis, MO, USA) and a polyclonal antibody against calbindin (1:250; Chemicon, Billerica, MA, USA) overnight at 4°C. Calmodulin is present in the cytoplasm of all hair cells of the mouse utricle sensory epithelium, while calbindin labels only Type I hair cells that reside predominantly in the striola (Dechesne et al. 1988). After additional PBS washes, the utricles were then incubated with secondary antibody (Alexa 594 goat anti-rabbit IgG 1:500 and Alexa 488 horse anti-mouse IgG 1:500; Invitrogen, Carlsbad, CA, USA) for 2 h at room temperature. Utricles were then washed in PBS and mounted in Fluoromount-G (Southern Biotech, Birmingham, AL, USA).
Utricles were examined using a Zeiss Axioplan II fluorescence microscope with FITC (green) and Texas Red (red) filter sets at ×40 magnification. Hair cell counts from four randomly selected 900 μm2 areas from the striolar and extrastriolar regions were determined (Cunningham et al. 2002). Sample sizes were 11–15 utricles per condition.
Minimum inhibitory concentration and minimum bactericidal concentration testing
All candidate drugs were tested at 200 μM concentration to determine whether they interfered with the known bactericidal activity of neomycin. Escherichia coli ATCC 25922 was used to inoculate the antibiotic dilutions. The MIC was tested in accordance with the National Clinical and Laboratory Standards Institute (Wikler 2006; Wikler 2007).
All values were calculated and presented as the mean value + 1 SD or the mean value + 1 SEM. Statistical analyses were performed using one-way ANOVA, two-way ANOVA, and student t-test (VassarStats: faculty.Vassar.edu/lowry/VassarStats.html). Significant ANOVA main effects and interactions were followed by appropriate pairwise comparisons using Tukey’s HSD test. Results were considered statistically significant if p < 0.05.
Candidate drugs identified by initial screen for protection and confirmed on retesting
Crosses blood/brain barrier
Topoisomerase 2 poison; used as chemotherapeutic agent. Used clinically in other countries, not yet FDA-approved
Yes (Cornford et al. 1992)
Beta-2 adrenergic blocker; used for treatment of hypertension, heartfailure. FDA-approved
Yes (Elsinga et al. 2004)
Plasma membrane stabilizer; used for the treatment of nasal allergy, snake venom hemolysis; possible chemotherapeutic adjunct. Used clinically in other countries, not yet FDA-approved
Yes (Okamoto et al. 2001)
Acetylcholinesterase inhibitor; used as antispasmodic. Used clinically in other countries, not yet FDA-approved
Yes (Kunysz et al. 1988)
Diuretic, Na/H exchange inhibitor. Derivative of amiloride, FDA-approved diuretic
Yes (Ferimer et al. 1995)
Alpha-1 adrenergic blocker; used as Antihypertensive. FDA-approved
Yes (Diop and Dausse 1986)
Anticholinergic; acetylcholinesterase inhibitor, used for treatment of Alzheimer’s dementia. FDA-approved
Yes (McNally et al. 1996)
Dose–response relationships were determined for drugs found to be protective upon the confirmatory testing. We refer to this group as candidate drugs. Two sets of dose–response relationships were determined for each candidate drug. In the first set of dose–response experiments, 5 dpf zebrafish larvae were pretreated for 1 h with each candidate drug at 0, 10, 50, 100, and 200 μM concentrations and then treated with 200 μM neomycin for 1 h with the candidate drug still present. Hair cell survival was calculated as a percentage of the hair cell counts from control animals treated identically, with pretreatment with 1% DMSO but no neomycin exposure. These experiments established dose-dependency and also assessed toxicity in the candidate drug's interaction with neomycin.
Hair cell survival (percent of control) after pretreatment with increasing doses of candidate protective drugs followed by 200 μM neomycin
28 ± 14
50 ± 11*
89 ± 19**
83 ± 19**
92 ± 11**
22 ± 6
72 ± 8**
92 ± 28**
97 ± 17**
28 ± 14
50 ± 22**
67 ± 19**
100 ± 22**
108 ± 17**
17 ± 11
39 ± 14*
75 ± 11**
83 ± 17**
22 ± 6
39 ± 17**
86 ± 19**
89 ± 22**
100 ± 17**
17 ± 11
39 ± 11*
72 ± 14**
86 ± 19**
89 ± 19**
17 ± 11
31 ± 11**
61 ± 14**
64 ± 17**
83 ± 19**
The lowest nontoxic pretreatment dose affording maximal protection against neomycin was determined for each drug and found to be as follows: 100 μM cepharanthine, 50 μM drofenine, 50 μM tacrine, 50 μM carvedilol, 50 μM amsacrine, 50 μM hexamethyleneamiloride, and 50 μM phenoxybenzamine.
Protection against variable doses of neomycin
Hair cell survival (percent of control) in the zebrafish lateral line after pretreatment with protective drug followed by variable doses of neomycin
Neomycin dose given after pretreatment
100 ± 10
37 ± 20
20 ± 10
13 ± 7
100 ± 15
83 ± 13*
93 ± 10*
77 ± 17*
100 ± 10
110 ± 17*
90 ± 13*
80 ± 20*
100 ± 11
100 ± 27*
87 ± 30*
97 ± 13*
100 ± 13
67 ± 20*
70 ± 13*
60 ± 13*
100 ± 11
90 ± 30*
80 ± 20*
73 ± 20*
100 ± 10
63 ± 7*
67 ± 10*
60 ± 13*
100 ± 12
80 ± 20*
87 ± 13*
67 ± 13*
Texas-Red conjugated gentamicin and FM1-43 uptake studies
Uptake of Texas Red-conjugated gentamicin and FM1-43 after pretreatment with candidate drugs
Texas Red–conjugated gentamicin uptake
Rapid FM1-43 uptake
Uptake of FM1-43 after a short, 45 s, exposure was blocked only by phenoxybenzamine. All other drugs tested demonstrated no impact on the rapid uptake of FM1-43 (Table 4). These results demonstrate that the screen identified some drugs that protect against aminoglycoside-induced hair cell death at the level of drug uptake and others that may affect intracellular pathways.
Inhibition of bactericidal activity
To be therapeutically effective, candidate drugs should not interfere with the bactericidal activity of aminoglycosides. None of the seven drugs significantly increased the minimum inhibitory concentration (MIC) or the minimum bactericidal concentration (MBC) of neomycin. All seven drugs demonstrated no greater than a twofold change in the minimum inhibitory concentration (2.0 μg/ml) and minimum bactericidal concentration (2.0 μg/ml) of neomycin. Up to a twofold increase is considered within the normal variation of the test (Wikler 2006; Wikler 2007). This indicates that co-administration of these protective drugs would not be expected to interfere with the desired antibacterial properties of neomycin.
Mouse utricle studies
To begin determining whether the intracellular protective effects revealed by our screening procedures are conserved in the mammalian inner ear, cepharanthine and tacrine were tested for their ability to protect mature mammalian inner ear hair cells from neomycin-induced hair cell death. Explants of mature mouse utricles were pretreated with these drugs with or without subsequent neomycin exposure.
Previously, our laboratory used the zebrafish lateral line to screen a small molecule library for protective agents (Owens et al. 2008). That study identified two chemicals (PROTO1 and 2) with protective effects against hair cell death. While PROTO1 and 2 are candidates for drug development, FDA approval of new drugs requires an average of 12 years and the odds of a new drug becoming approved are approximately one out of 5,000 (Wierenga and Eaton 1993). Applying the same screen to the NINDS Custom Collection is potentially more efficient. Compounds in this library have proven drug-like properties such as solubility and cell permeability in contrast to the less well-characterized small molecule libraries. Use of this library bypasses certain aspects of drug development and moves more rapidly towards identifying an “ideal” candidate protective drug as defined above. By evaluating the seven candidate protective drugs identified in the screen with regards to these six characteristics, tacrine was identified as a protective drug worthy of future study.
Safety of administration
In searching for a protective compound for the inner ear, ease of administration is an important factor. Some compounds are not practical for systemic administration or may only be effective when delivered directly to the inner ear (e.g. JNK inhibitors and caspase inhibitors; Wang et al. 2003; Zine and van de Water 2004). Systemic administration avoids the need for invasive intracochlear or transtympanic drug applications. All seven of the candidate drugs have been used systemically in humans, although only carvedilol, tacrine, and phenoxybenzamine are currently FDA-approved. The others have been used in experimental protocols or countries outside of the USA.
The clinical uses for these drugs provide insight into their potential as protective drugs. Amsacrine is a topoisomerase II poison and is generally cytotoxic (Rowe et al. 1986) and thus impractical for systemic use as an inner ear protectant. Hexamethyleneamiloride is a Na/H-exchange blocker used as a diuretic (Davies and Solioz 1992). Phenoxybenzamine (alpha-adrenergic blocker) and carvedilol (beta-adrenergic blocker) are both used to treat hypertension (Osnes et al. 2000). Cepharanthine has membrane-stabilizing activity and is used for treatment of nasal allergy and snake venom hemolysis (Furusawa and Wu 2007; Kohno et al. 1987). Drofenine and tacrine are acetylcholinesterase inhibitors used for muscle relaxation and Alzheimer’s dementia, respectively (Bodur et al. 2001; Drukarch et al. 1987).
Blood–brain barrier penetration
All seven drugs cross the blood–brain barrier (Table 1). The kinetics of inner ear penetration for these drugs is unknown. It is also unknown whether crossing the blood–brain barrier is critical for a potential inner ear protectant, however this would seem to improve the odds of diffusion into the perilymph and possibly endolymph.
Protection against a wide-range of aminoglycoside doses
The ideal protective drug would protect hair cells over a wide range of aminoglycoside dosages. The efficiency of testing in the zebrafish permits thorough investigation of hair cell protection. We tested a range of concentrations of each protectant and tested each protectant against a range of neomycin concentrations. Testing a range of protectant concentrations is important because some protectants have been found to be toxic at higher concentrations. In addition, protective compounds effective against a narrow range of aminoglycoside concentrations may have limited clinical utility (Sugahara et al. 2006). In this study, all candidate drugs were protective against a wide range of neomycin doses in the zebrafish lateral line, preserving a range of 60% to 100% of the hair cells.
We hypothesize that the variability in the magnitude of protective effects is due to differential effects on the multiple death pathways activated by aminoglycoside exposure. The mechanisms underlying aminoglycoside-induced hair cell death remain controversial, with both caspase-dependent and caspase-independent pathways implicated (Cunningham et al. 2002; Matsui et al. 2003; Jiang et al. 2006). Inhibition of one death pathway likely still allows (or possibly even facilitates) death through alternate pathways (Lin et al. 1999; Yu et al. 2004). Although some of the drugs identified in this study achieved complete protection in the lateral line, ultimately, a protective “cocktail” composed of multiple drugs may be a more effective regimen for prevention of hair cell death.
Effects on aminoglycoside uptake
Three candidate drugs, drofenine, tacrine, and cepharanthine, did not affect TR-Gent uptake. Ideally, a protective drug identified in this neomycin-driven screen would inhibit intracellular death pathways triggered by an aminoglycoside rather than inhibiting aminoglycoside uptake. This drug would have more potential applications against a wider variety of causes of hair cell death.
While our tendency is to focus on drugs that affect cell death pathways, it is important to recognize that drugs that blocked aminoglycoside uptake may also have clinical relevance. These drugs could be administered systemically or locally to block ototoxicity of the aminoglycoside without affecting its bactericidal capacity or perturbing intracellular pathways. Hexamethyleneamiloride, amsacrine, carvedilol, and phenoxybenzamine blocked the uptake of TR-Gent. Hexamethyleneamiloride, as an amiloride derivative, is likely to block the mechanotransduction channel. The mechanisms of blockade by carvedilol, amsacrine, and phenoxybenzamine are unknown. Of these drugs, only phenoxybenzamine also affected FM1-43 uptake. This differential blockade between FM1-43 and TR-Gent suggests either different mechanisms of uptake, differing sensitivity to channel blockade, or different sensitivities of our detection methods.
Effects on bactericidal activity of aminoglycoside
None of the seven drugs affected the bactericidal activity of neomycin. This has obvious importance for potential use as an aminoglycoside-specific protective drug.
Protection in mammalian tissue
Hair cell protection in the zebrafish lateral line does not assure protection in mammalian hair cells, and thus testing was performed in the mouse utricle.
Due to the more time-consuming nature of mammalian testing, only two of the seven drugs were tested in the utricle, cepharanthine and tacrine. These two drugs were chosen because they were effective protective drugs that did not inhibit aminoglycoside uptake. Tacrine demonstrated significant protection against neomycin-induced hair cell death in mouse utricle explants. In contrast, cepharanthine was found to cause hair cell death at moderate concentrations, and thus further experiments examining its protective effects were not conducted. Tacrine is particularly interesting because its derivative, bis(7)-tetrahydroacridine, stabilizes the mitochondrial membrane potential and has been used experimentally as a neuroprotectant (Fu et al. 2006; Fu et al. 2007).
The lack of hair cell protection by cepharanthine in the mouse utricle demonstrates the importance of confirming findings from zebrafish in mammalian systems. However, there are critical differences between the exposure conditions of lateral line hair cells and free-floating utricle hair cells. Free-floating utricles have been removed from the organism, and thus any neural input has been removed. Secondly, lateral line hair cells are exposed to drugs predominantly at their apices, while free-floating utricles are bathed circumferentially. Lastly, one can hypothesize that hair cells in vitro may be more fragile and susceptible to cell death than hair cells in vivo.
This study represents the first screen of a library of compounds with known bioactivity for drugs that protect against aminoglycoside-induced hair cell death. Further evaluation of the screen identified tacrine as a particularly promising drug. Tacrine demonstrates protection against a wide range of neomycin doses, can be administered systemically, crosses the blood–brain barrier, does not inhibit aminoglycoside uptake, does not interfere with the bactericidal activity of neomycin, and is effective in mammalian utricle explants. Tacrine also has known targets as an acetylcholinesterase inhibitor and stabilizer of mitochondrial membrane potential. Tacrine is thus an excellent candidate for further investigation through in vivo testing, evaluation of its mechanism of action (cholinergic versus off-target effects), and evaluation of its potential as a protective drug against other challenges such as cisplatin, noise, and even aging.
The results of this screen are not meant to suggest that none of the other compounds in the library have protective effects. In particular, many antioxidants are known to protect against hair cell death and were not detected in the screen. Varying the screening conditions would likely identify additional protective drugs and is worthy of future study. For example, protection against hair cell death in the zebrafish lateral line has been shown to require a 24-h exposure to antioxidants such as D-methionine and glutathione (Ton and Parng 2005).
Some protection may be due to global effects on the organism (e.g. increasing renal clearance of neomycin) rather than specific effects on the hair cell. We think this is unlikely since aminoglycosides appear to enter lateral line hair cells directly from the medium rather than depending on circulation or tissue accumulation.
It is important to note that tacrine has known hepatotoxicity that has hindered its use for the treatment of Alzheimer’s dementia. In a multicenter clinical trial of tacrine, 49% of patients demonstrated an elevation of liver transaminases at a mean of 50 days after initiation of therapy (Watkins et al. 1994). Most of these patients were asymptomatic and had a return to normal liver function levels after withdrawal of the drug. Of the patients that had tacrine therapy resumed, 88% were able to resume long-term use of the drug. A number of possible mechanisms for this hepatotoxicity have been implicated, including poisoning of topoisomerases (Mansouri et al. 2003). It is likely that this toxicity occurs via a separate mechanism from its protective effect seen in hair cells. It may be possible to decrease the tacrine dose to minimize toxicity while maintaining its protective effects in hair cells. In addition, it is likely that for hair cell protection protocols, tacrine would be administered for days to weeks, rather than the months to years required for treatment of Alzheimer’s dementia. Tacrine hybrid compounds are currently being developed (Fang et al. 2008) with potent activity but reduced hepatotoxicity. It remains to be seen whether these modifications would also reduce the protective effects seen in hair cells.
Limited mammalian data are presented due to the time-consuming nature of mammalian experiments. Additional studies are imperative for further progress. Lateral line hair cells have important differences from inner ear hair cells. There is no separation of fluid spaces in the lateral line so the apical surfaces of hair cells extend into the surrounding water. In addition, since there is no stria vascularis, drugs that act through strial mechanisms will not be identified. We view the screen as an efficient method for rapidly identifying candidate drugs that must then be confirmed in the mammalian inner ear.
This research was supported by grants from NIH/NIDCD: DC0018, DC04661, DC05987, DC07613, the National Organization for Hearing Research, NIH/NCRR: C06RR015455, C06RR14516, and the University of Washington Royalty Research Fund. The authors would like to thank Glen MacDonald, Mae Del Puerto, Brock Roberts, and Sue Swanzy for their technical expertise.